Jean-François Formela

Jean-François Formela is a partner at Atlas Venture who focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. He is chairman of IFM and Triplet Therapeutics and serves on the boards of Intellia Therapeutics (NASDAQ: NTLA), F-star, Korro Bio, Spero Therapeutics (NASDAQ: SPRO), and Translate Bio (NASDAQ: TBIO) which he co-founded. Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), Arteaus Therapeutics (acquired by Eli Lilly), deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), and NxStage (NASDAQ: NXTM, acquired by Fresenius Medical). He was also an investor in CoStim Pharmaceuticals (acquired by Novartis). Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough, where he directed U.S. Phase 4 studies in all therapeutic areas. Prior to that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon therapy. Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris. Jean-François is a member of the Massachusetts General Hospital Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art. He received his M.D. from Paris University School of Medicine, and his M.B.A. from Columbia University.